SCHEMBL22358017

SCHEMBL22358017

CC(C)(C)OC(=O)N1CC=C(c2nsc(-c3ccc4cnn(C5COC5)c4c3)n2)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 4/20 0.41
PDK4 Q16654 1/20 0.40
NAMPT P43490 1/20 0.40
JAK1 P23458 1/20 0.39
CDK7 P50613 1/20 0.39
CDK13 Q14004 1/20 0.39
CDK12 Q9NYV4 1/20 0.39
WNT3A P56704 1/20 0.38
KIT P10721 3/20 0.38
SCN9A Q15858 1/20 0.37
EED O75530 1/20 0.37
RBBP4 Q09028 1/20 0.37
SUZ12 Q15022 1/20 0.37
EZH2 Q15910 1/20 0.37
LIPC P11150 1/20 0.37
LIPG Q9Y5X9 1/20 0.37
GRM5 P41594 2/20 0.37
GRM1 Q13255 2/20 0.37
ATR Q13535 1/20 0.36
BTK Q06187 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20116505 0.94 GPR119 (0.41) GPR119PDK4NAMPTJAK1CDK7
SCHEMBL20676212 0.86 NAMPT (0.43) GPR119PDK4NAMPTJAK1CDK7
SCHEMBL20676569 0.83 GPR119 (0.46) GPR119PDK4NAMPTJAK1CDK7
SCHEMBL20117077 0.83 WNT3A (0.49) GPR119NAMPTJAK1CDK7CDK13
SCHEMBL20116417 0.83 GPR119 (0.33) GPR119JAK1CDK7CDK13CDK12
SCHEMBL20116530 0.81 GPR119 (0.48) GPR119WNT3AATR
SCHEMBL22358258 0.78 GPR119 (0.41) GPR119PDK4NAMPTJAK1CDK7
SCHEMBL20116147 0.78 GPR119 (0.48) GPR119ATR
SCHEMBL21796569 0.74 NAMPT (0.45) GPR119PDK4NAMPTJAK1CDK7
SCHEMBL20676531 0.74 GPR119 (0.51) GPR119WNT3AATR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 US disclosed
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 US disclosed
US-20200262828-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2020-08-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11873298-B2 Compounds and uses thereof NLN, ACHE, CLN6 GPR119 2922/4885PDK4 1896/4885NAMPT 473/4885
US-20200262828-A1 COMPOUNDS AND USES THEREOF NLN, ACHE, CLN6 GPR119 2922/4885PDK4 1896/4885NAMPT 473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.